Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that the Phase...
Drug
China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD
China Medical System Holdings Limited (CMS) (HKG: 0867) announced today that the National Medical Products...
Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the US Food and Drug...
Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment
Novo Nordisk (NYSE: NVO) announced today that the European Commission (EC) has granted marketing authorization...
Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management
Lepu Medical Technology (SHE: 300003) announced on July 15, 2026, that the National Medical Products...
Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus
Merck KGaA (ETR: MRK) announced on July 8, 2026, that the US Food and Drug...
Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H/dMMR Colon Cancer
Innovent Biologics (HKG: 1801) announced that its independently developed Daboxin (ipilimumab N01) has received marketing...
Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that its Phase III clinical study evaluating sacituzumab...
CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination
CSPC Pharmaceutical Group (HKG: 1093) announced that its self-developed docetaxel (albumin-bound) (HB1801) and Anbenitamab (KN026)—developed...
Biogen Advances Diranersen into Phase 3 Development Following Positive Alzheimer’s Phase 2 Data
Biogen Inc. (NASDAQ: BIIB) presented positive Phase 2 CELIA study data for diranersen (BIIB080), an...
Sino Biopharmaceutical’s TRD205 Secures NMPA Breakthrough Therapy Designation for Chronic Post-Surgical Neuropathic Pain
Sino Biopharmaceutical (HKG: 1177) announced that TRD205, a Category 1 innovative drug self-developed by its...
Lynk Pharmaceuticals Completes Phase 3 Enrollment for Zemprocitinib in Ankylosing Spondylitis Trial
Lynk Pharmaceuticals Co., Ltd. announced that enrollment has been completed for zemprocitinib capsules, a second-generation...
Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the Investigational New Drug (IND) application...
B&K Corporation Completes Patient Enrollment in Phase II Diabetic Foot Ulcer Trial for Pro-101-2 rhPDGF-BB Therapy
B&K Corporation Limited (HKG: 2396) announced the completion of patient enrollment in its Phase II...
Huadong Medicine’s Subsidiary Secures NMPA Approval for First-in-Class Trispecific Agonist DR10624 in Heart Failure Treatment
Huadong Medicine Co., Ltd. (SHE: 000963) announced that the clinical trial application for DR10624 injection,...
Hengrui Pharmaceuticals Secures NMPA Clinical Trial Approval for SHR-3079 in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that SHR-3079 injection has received...
Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its Category 1 chemical...
Fosun Pharma Secures NMPA Approval for Phase 1 Trial of HLX37 Bispecific Antibody in Combination Therapies for Advanced Solid Tumors
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that China’s National Medical...
Haisco Submits NMPA Marketing Application for Crisugabalin’s New Indication in Neuropathic Pain Treatment
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that it has submitted a marketing application...
Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection – Novel Bispecific Antibody Therapy for Thyroid Eye Disease
Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced that China’s National Medical Products Administration (NMPA)...